CL2013002573A1 - Composición que comprende un extracto o preparación de heces humanas; metodo para reemplazar o complementar o modificar la microbiota de colon de un sujeto; uso de dicha composicion para tratar enfermedad o afección patológica o iatrogénica del colon. - Google Patents

Composición que comprende un extracto o preparación de heces humanas; metodo para reemplazar o complementar o modificar la microbiota de colon de un sujeto; uso de dicha composicion para tratar enfermedad o afección patológica o iatrogénica del colon.

Info

Publication number
CL2013002573A1
CL2013002573A1 CL2013002573A CL2013002573A CL2013002573A1 CL 2013002573 A1 CL2013002573 A1 CL 2013002573A1 CL 2013002573 A CL2013002573 A CL 2013002573A CL 2013002573 A CL2013002573 A CL 2013002573A CL 2013002573 A1 CL2013002573 A1 CL 2013002573A1
Authority
CL
Chile
Prior art keywords
colon
composition
microbiota
pathological
complement
Prior art date
Application number
CL2013002573A
Other languages
English (en)
Spanish (es)
Inventor
Michael J Sadowsky
Alexander Khoruts
Alexa R Weingarden
Matthew J Hamilton
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of CL2013002573A1 publication Critical patent/CL2013002573A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/24—Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
CL2013002573A 2011-03-09 2013-09-06 Composición que comprende un extracto o preparación de heces humanas; metodo para reemplazar o complementar o modificar la microbiota de colon de un sujeto; uso de dicha composicion para tratar enfermedad o afección patológica o iatrogénica del colon. CL2013002573A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161450838P 2011-03-09 2011-03-09

Publications (1)

Publication Number Publication Date
CL2013002573A1 true CL2013002573A1 (es) 2014-04-11

Family

ID=46798573

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013002573A CL2013002573A1 (es) 2011-03-09 2013-09-06 Composición que comprende un extracto o preparación de heces humanas; metodo para reemplazar o complementar o modificar la microbiota de colon de un sujeto; uso de dicha composicion para tratar enfermedad o afección patológica o iatrogénica del colon.

Country Status (13)

Country Link
US (12) US9968638B2 (zh)
EP (4) EP3610881A1 (zh)
JP (1) JP2014507481A (zh)
CN (1) CN103561752B (zh)
AU (5) AU2012225305B2 (zh)
BR (1) BR112013022927A2 (zh)
CA (2) CA2829385C (zh)
CL (1) CL2013002573A1 (zh)
ES (1) ES2636439T3 (zh)
MX (1) MX2013010343A (zh)
PL (1) PL2683390T3 (zh)
SG (1) SG193348A1 (zh)
WO (1) WO2012122478A1 (zh)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
PL3564357T3 (pl) 2010-02-01 2022-08-08 Rebiotix, Inc. Bakterioterapia zapalenia jelita grubego z clostridium difficile
EP2600877A4 (en) 2010-08-04 2014-05-07 Borody Thomas J COMPOSITIONS FOR FLORAL TRANSPLANTATION OF FECAL MATERIALS AND METHODS OF MAKING AND USING SAME, AND DEVICES FOR THEIR ADMINISTRATION
JP2014507481A (ja) 2011-03-09 2014-03-27 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 結腸微生物相移植のための組成物及び方法
WO2014152484A1 (en) * 2013-03-14 2014-09-25 Regents Of The University Of Minnesota Freeze dried fecal microbiota for use in fecal microbial transplantation
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
WO2013090825A1 (en) 2011-12-15 2013-06-20 Pureflora, Inc. Device for the collection, refinement, and administration of gastrointestinal microflora
EP2836224A4 (en) 2012-02-29 2015-12-16 Ethicon Endo Surgery Inc COMPOSITIONS OF BIOZOOSE AND RELATED METHODS
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
BR112015012123A8 (pt) * 2012-11-26 2018-01-23 Borody Thomas J composições para a recuperação de uma microbiota fecal e métodos para produzir e usar as mesmas.
EP2951285A4 (en) 2013-02-04 2016-10-26 Seres Therapeutics Inc COMPOSITIONS AND METHODS FOR INHIBITING THE GROWTH OF PATHOGENIC BACTERIA
US10973861B2 (en) 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
CN103330961B (zh) * 2013-02-08 2016-06-08 南京法迈特科技发展有限公司 一种医用腔道内容物目标成分回收器械
EP2967077A4 (en) * 2013-03-15 2016-09-14 Seres Therapeutics Inc MICROBIAL COMPOSITIONS AND ASSOCIATED METHODS BASED ON A NETWORK
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
EP4234011A3 (en) * 2013-06-05 2023-09-20 Rebiotix, Inc. Microbiota restoration therapy (mrt), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10058576B2 (en) 2013-10-03 2018-08-28 The Trustees Of The University Of Pennsylvania Compositions and methods comprising a defined microbiome and methods of use thereof
CA2926466C (en) * 2013-10-03 2021-11-16 Frederic Bushman Compositions comprising a defined microbiome and methods of use thereof
AU2014352643A1 (en) 2013-11-25 2016-06-30 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
EP3107553B1 (en) * 2014-02-18 2021-12-01 Universitätsklinikum Jena Methods and compositions for intestinal microenvironment transfer
CN104546937B (zh) * 2014-09-30 2019-02-01 深圳华大基因科技有限公司 系结梭菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
GB2551642B (en) 2014-10-31 2020-09-23 Pendulum Therapeutics Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
SI3193901T1 (en) 2014-12-23 2018-06-29 4D Pharma Research Limited Pirin polypeptide and immune modulation
NO3065748T3 (zh) 2014-12-23 2018-04-21
CN107708715B (zh) * 2015-04-13 2022-06-03 普梭梅根公司 用于微生物组功能特征相关的状况的微生物组来源的诊断和治疗的方法及系统
FR3035328B1 (fr) 2015-04-24 2019-08-23 Maat Pharma Procede de preparation d'un echantillon de microbiote fecal
FR3035317B1 (fr) 2015-04-24 2019-06-14 Maat Pharma Dispositif de prelevement de micro-organismes, kit de prelevement comprenant un tel dispositif et procede de prelevement mettant en œuvre un tel dispositif
AU2016202831B2 (en) * 2015-05-08 2021-11-18 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
DK3294073T3 (da) 2015-05-11 2022-11-14 Mybiotics Pharma Ltd Systemer og fremgangsmåder til dyrkning af en biofilm af probiotiske bakterier på faste partikler til kolonisering af bakterier i tarmen
KR102561989B1 (ko) * 2015-05-14 2023-07-31 핀치 테라퓨틱스 홀딩스 엘엘씨 대변 균무리 이식용 조성물, 및 이의 제조 및 사용 방법, 및 이의 전달을 위한 장치
AU2016268158B2 (en) 2015-05-22 2022-03-17 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
CN104922158B (zh) * 2015-06-05 2018-11-02 中国人民解放军第三军医大学第三附属医院 粪菌胶囊及其制备与应用
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
CA2986915C (en) * 2015-06-09 2023-09-19 Rebiotix, Inc. Microbiota restoration therapy (mrt) compositions and methods of manufacture
SG10201912324XA (en) 2015-06-15 2020-02-27 4D Pharma Res Ltd Compositions comprising bacterial strains
ME03563B (me) 2015-06-15 2020-07-20 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
HUE044617T2 (hu) 2015-06-15 2019-11-28 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
AU2016321319A1 (en) * 2015-09-09 2018-04-26 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for eczema
CN108472315A (zh) 2015-10-26 2018-08-31 克雷斯顿沃控股公司 用于粪便微生物群相关疗法的组合物及方法
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MD3209310T2 (ro) 2015-11-20 2018-06-30 4D Pharma Res Ltd Compoziții care conțin tulpini bacteriene
FR3045383B1 (fr) * 2015-12-18 2019-06-14 Maat Pharma Procede de lyophilisation d'un echantillon de microbiote fecal
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
CN114712405A (zh) 2016-03-04 2022-07-08 4D制药有限公司 包含细菌菌株的组合物
US20190076491A1 (en) * 2016-03-10 2019-03-14 Peachtree Health Management Llc Dba Aeon Laboratories Methods of treating substance abuse related diseases or disorders
JP7198087B2 (ja) 2016-05-25 2022-12-28 マイバイオティクス ファーマ リミテッド 微生物叢療法のための組成物及び方法
JP2019520340A (ja) * 2016-06-01 2019-07-18 クレストヴォ・ホールディングス・エルエルシー 炎症性腸疾患（ｉｂｄ）および他の障害を治療するための組成物および方法
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US20180000872A1 (en) * 2016-07-01 2018-01-04 Regents Of The University Of Minnesota Compositions and methods for c. difficile treatment
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
JP2019524744A (ja) * 2016-07-19 2019-09-05 エーオーバイオーム， エルエルシー．ＡＯＢｉｏｍｅ， ＬＬＣ． 使用および消化器系への送達のためのアンモニア酸化微生物
US20180030403A1 (en) 2016-07-28 2018-02-01 Bobban Subhadra Devices, systems and methods for the production of humanized gut commensal microbiota
US20180036352A1 (en) * 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
WO2018071534A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating irritable bowel syndrome and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US20200188449A1 (en) 2016-10-11 2020-06-18 Crestovo Holdings Llc Compositions and Methods for Treating Chronic Fatigue Syndrome and Related Disorders
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US20200061127A1 (en) 2016-11-11 2020-02-27 Arizona Board Of Regents On Behalf Of Arizona State University Methods and Compositions for Changing Metabolite Levels in a Subject
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
CN106665436A (zh) * 2017-01-26 2017-05-17 中国水产科学研究院黑龙江水产研究所 一种移植健康鱼肠道粪便以治疗患病鱼的方法
FR3062063B1 (fr) * 2017-01-26 2019-04-19 Centre National De La Recherche Scientifique Microbiote fecal pour traiter des patients subissant une greffe de cellules souches hematopoietiques
US20200147151A1 (en) * 2017-01-30 2020-05-14 The Board Of Regents Of The University Of Texas System Compositions and methods for fecal microbiota transplantation
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
CN110831606A (zh) 2017-04-05 2020-02-21 克雷斯顿沃控股公司 治疗帕金森氏病(pd)和相关疾病的组合物和方法
EP3630137B1 (en) 2017-05-22 2023-05-17 4D Pharma Research Limited Compositions comprising bacterial strains
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
EP3630190B1 (en) 2017-05-26 2024-02-21 Finch Therapeutics Holdings LLC Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
WO2018218211A1 (en) * 2017-05-26 2018-11-29 Animal Microbiome Analytics, Inc. Products and methods for therapeutic administration of microorganisms to non-human animals
SI3638271T1 (sl) 2017-06-14 2021-01-29 4D Pharma Research Limited Sestavki, ki vsebujejo bakterijske seve
PL3600364T3 (pl) 2017-06-14 2021-01-11 4D Pharma Research Limited Kompozycje zawierające szczep bakteryjny z rodzaju megasphaera i ich zastosowania
WO2019032572A1 (en) * 2017-08-07 2019-02-14 Finch Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DECOLONIZING ANTIBIOTIC-RESISTANT BACTERIA IN INTESTINES
US11865145B2 (en) 2017-08-07 2024-01-09 Finch Therapeutics Holdings Llc Compositions and methods for maintaining and restoring a healthy gut barrier
RU2020110462A (ru) 2017-08-14 2021-09-16 Серес Терапеутикс, Инк. Композиции и способы для лечения холестатического заболевания
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
EP3453395B1 (en) * 2017-09-08 2023-10-18 Deutsches Rheuma-Forschungszentrum Berlin Anaeroplasmatales for use in the treatment or prevention of an inflammatory disorder of the digestive system
MX2020002659A (es) * 2017-09-08 2020-09-09 Evelo Biosciences Inc Vesiculas extracelulares bacterianas.
US20210121503A1 (en) 2017-10-12 2021-04-29 Crestovo Holdings Llc Fecal microbiota transplantation for treating ulcerative colitis
CN108531417A (zh) * 2018-03-05 2018-09-14 成都知己基因生物科技有限公司 一种分解膳食纤维的肠道有益菌的制备方法及产品
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
US10709744B1 (en) 2019-03-28 2020-07-14 Mybiotics Pharma Ltd. Probiotic biofilm suppositories
EP3996727A4 (en) * 2019-07-11 2023-03-15 Milis, Antony PROCEDURE FOR PREPARING INTESTINAL MUCOA FOR IMPROVING MICROBIAL COLONIZATION
CN114650833A (zh) 2019-09-13 2022-06-21 芬奇治疗控股有限责任公司 用于治疗孤独症谱群障碍的组合物和方法
US20240131082A1 (en) 2019-10-18 2024-04-25 Finch Therapeutics Holdings Llc Compositions and Methods for Delivering a Bacterial Metabolite to a Subject
WO2021096794A1 (en) * 2019-11-11 2021-05-20 Hazan Sabine Method of treating an individual with a health condition with fecal microbiota transplant
WO2021097288A1 (en) 2019-11-15 2021-05-20 Finch Therapeutics Holdings Llc Compositions and methods for treating neurodegenerative diseases
CN116209750A (zh) * 2019-12-20 2023-06-02 西奈山伊坎医学院 用于治疗炎症性肠病的组合物和方法
EP3872163A4 (en) 2019-12-30 2022-10-26 Qihui Biotechnology (Yangzhou) Co., Ltd. DEVICE AND PROCESS FOR SEPARATION AND RECOVERY OF THE CONTENTS OF GUTS AND EXTRACT
WO2021142358A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for treating hepatic encephalopathy (he)
WO2021142353A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for treating hepatitis b (hbv) and hepatitis d (hdv)
WO2021142347A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for non-alcoholic steatohepatitis (nash)
US11744866B2 (en) 2020-03-18 2023-09-05 Sabine Hazan Methods of preventing and treating COVID-19 infection with probiotics
US20230201265A1 (en) 2020-03-31 2023-06-29 Finch Therapeutics Holdings Llc Compositions comprising non-viable fecal microbiota and methods of use thereof
WO2022178294A1 (en) 2021-02-19 2022-08-25 Finch Therapeutics Holdings Llc Compositions and methods for providing secondary bile acids to a subject
EP4056167A1 (en) * 2021-03-12 2022-09-14 Lietuvos Sveikatos Mokslu Universitetas Modification of fecal microbiota with rectal suppositories

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1118403B (de) 1960-01-27 1961-11-30 Hoechst Ag Verfahren zur Gewinnung von antitumorwirksamen Sporen
FR1275M (fr) 1961-05-06 1962-05-02 Rene Roger Médicament a base de colibacilles vivants.
NL294835A (zh) 1962-07-19 1900-01-01
FR2828M (fr) 1963-03-01 1964-11-02 Lucien Nouvel Médicament renfermant des colibacilles antibiorésistants.
FR5528M (zh) 1965-10-01 1967-11-13
GB1271674A (en) 1968-07-09 1972-04-26 Nisshin Flour Milling Co Process and preparation for treating diarrhoea in pigs
SE371209B (zh) 1969-10-13 1974-11-11 Cernelle Ab
US3734154A (en) 1971-04-23 1973-05-22 Packaging Ass Inc Disposable bag with self-closing valve
DE2134179A1 (de) 1971-07-09 1973-01-25 Rolf Dr Schuler Bifidobakterien enthaltendes praeparat und verfahren zur herstellung desselben
FR2244464A1 (en) 1973-06-26 1975-04-18 Serozym Laboratoires Yeast, lacto- and colibacillus based compsns - used to modify intestinal flora, treat colitis and digestive disorders, etc.
US4098728A (en) * 1976-01-02 1978-07-04 Solomon Rosenblatt Medical surgical sponge and method of making same
US4335107A (en) 1978-06-05 1982-06-15 Snoeyenbos Glenn H Mixture to protect poultry from salmonella
CH637297A5 (fr) 1978-12-05 1983-07-29 Nestle Sa Microbille comprenant un microorganisme et son procede de fabrication.
US4536409A (en) 1981-01-23 1985-08-20 American Can Company Oxygen scavenger
US4452779A (en) 1982-02-03 1984-06-05 Cockerill Vernon Composition and method of treating lactating mammals
CA1241886A (en) 1983-04-13 1988-09-13 Peter W. Field Enema bag
FI840816A0 (fi) 1984-03-01 1984-03-01 Farmos Oy Bakteriepreparat
JPS615022A (ja) 1984-06-19 1986-01-10 Advance Res & Dev Co Ltd 腸内細菌叢改善剤
US4892731A (en) 1986-12-11 1990-01-09 Tadashi Arai Biological intestinal antiseptics
IL86859A (en) 1987-07-10 1991-12-15 E Z Em Inc Aqueous cathartic solution containing inorganic salts
US4948734A (en) 1987-08-12 1990-08-14 Mycogen Corporation Novel isolates of bacillus thuringiensis having activity against nematodes
ATE165738T1 (de) 1988-08-02 1998-05-15 Gastro Services Pty Ltd Behandlung von gastro-intestinalen krankheiten
US5443826A (en) * 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US5213807A (en) 1990-05-03 1993-05-25 Chemburkar Pramod B Pharmaceutical composition containing ibuprofen and a prostaglandin
JP2961184B2 (ja) 1990-05-07 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
US5266315A (en) 1990-05-07 1993-11-30 Kabushiki Kaisha Miyarisan Seibutsu Igaku Kenkyusho Composite for Clostridium difficile diarrhea and pseudomembranous colitis
US5116754A (en) 1990-10-04 1992-05-26 Fraser Ann D E Separation of bacteria from organic matter
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
JP3047143B2 (ja) 1992-04-24 2000-05-29 堀井薬品工業株式会社 腸管洗浄液用組成物及び腸管洗浄液
JP3850891B2 (ja) 1994-03-01 2006-11-29 ゼリア新薬工業株式会社 緩下効果を有する組成物
JPH07242557A (ja) 1994-03-03 1995-09-19 Ss Pharmaceut Co Ltd 乳酸菌含有瀉下薬組成物
US6984513B2 (en) 1994-03-03 2006-01-10 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
HU220190B (hu) 1994-05-26 2001-11-28 Bracco S.P.A. Humán eredetű Lactobacillus törzsek, ilyen törzseket tartalmazó gyógyászati készítmények és alkalmazásuk
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
AUPM864894A0 (en) 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
US5800821A (en) 1995-03-10 1998-09-01 New England Medical Center Hospitals, Inc. Bacterial spores as a heat stable vaccine delivery system
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5858356A (en) 1995-12-21 1999-01-12 Abbott Laboratories Lactobacillus acidophilus to inhibit cryptosporidiosis in mammals
US5902578A (en) 1996-03-25 1999-05-11 Abbott Laboratories Method and formula for the prevention of diarrhea
US5837238A (en) 1996-06-05 1998-11-17 Biogaia Biologics Ab Treatment of diarrhea
US6087386A (en) 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
AU1819897A (en) 1996-09-26 1998-04-17 Cuperman, Vladimir Borisovich Medicinal prophylactic "trisan"
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US6162464A (en) 1997-03-31 2000-12-19 Inkine Pharmaceutical, Inc. Non-aqueous colonic purgative formulations
US7374753B1 (en) 1997-06-03 2008-05-20 Ganeden Biotech, Inc. Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS
US6428783B1 (en) 1998-03-11 2002-08-06 Medtech Center, Inc. Bank of autochthonous strains of microorganisms and methods of its use for recovery of intestinal microbiocenosis of the men
US5902743A (en) 1998-03-20 1999-05-11 Wisconsin Alumni Research Foundation Probiotic bifidobacterium strain
EP1077252A1 (en) 1998-05-06 2001-02-21 Keijiro Nakamura Microbial culture liquors containing microorganisms differing in characteristics and living in symbiosis and metabolites thereof, carriers and adsorbents containing the active components of the culture liquors and utilization of the same
US6368591B2 (en) 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
AT407008B (de) 1998-08-06 2000-11-27 Viernstein Helmut Dr Formulierungen mit probiotisch wirksamen mikroorganismen
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
CA2343051A1 (en) 1998-09-17 2000-03-23 North American Vaccine, Inc. Streptococcal c beta protein compositions
EP1005863A1 (en) 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
AU1543400A (en) 1998-12-11 2000-07-03 Urex Biotech Inc. Oral administration of lactobacillus for the treatment and prevention of urogenital infection
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
CN1183904C (zh) 1999-02-26 2005-01-12 盐野义制药株式会社 改进了服用性的咀嚼型软胶囊剂及其制法
FR2808689B1 (fr) 2000-05-11 2004-09-03 Agronomique Inst Nat Rech Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs
JP2001327280A (ja) 2000-05-23 2001-11-27 Lion Corp 菌用凍結保存液
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US20040062757A1 (en) 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
US6756032B1 (en) 2000-07-12 2004-06-29 The Procter & Gamble Company Method to enhance and/or prolong the effects of a primary challenge to a responsive system with a secondary challenge
AU2001272369A1 (en) 2000-07-17 2002-01-30 Chr. Hansen A/S Methods and formultations with probiotic microorganisms and medicaments
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US7214370B2 (en) 2000-12-18 2007-05-08 Probiohealth, Llc Prebiotic and preservative uses of oil-emulsified probiotic encapsulations
US6790453B2 (en) 2001-03-14 2004-09-14 Mccormick & Company, Inc. Encapsulation compositions and process for preparing the same
US7815956B2 (en) 2001-04-27 2010-10-19 Pepsico Use of erythritol and D-tagatose in diet or reduced-calorie beverages and food products
EA006398B1 (ru) 2001-06-01 2005-12-29 Поузен Инк. Фармацевтические композиции для координированной доставки нестероидных противовоспалительных лекарственных средств
CN100366239C (zh) 2001-07-05 2008-02-06 涌永制药株式会社 软胶囊剂
PE20030284A1 (es) * 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de bifidobacterium
US20030092724A1 (en) 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
GB0124580D0 (en) 2001-10-12 2001-12-05 Univ Reading New composition
EP2425821B1 (en) 2002-04-05 2017-05-10 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
CA2391422A1 (en) 2002-07-12 2004-01-12 David William Molloy Rifampin (rifadin, rimactone, rifampicin) and doxycycline, (doryx, vibramycin) and the tetracyclines and other compounds currently classified as antibiotics and anti-tuberculous drugs as a treatment to prevent, modify disease progression and/or improve symptoms for neurodegenerative diseases including alzheimers disease, lewy body dementia, schizophrenia,...
IL152127A0 (en) 2002-10-06 2003-05-29 Bio Balance Corp Probiotic compositions for the treatment of inflammatory bowel disease
EP1514527A3 (en) 2003-05-06 2005-10-26 Spinal Innovations, LLC Artificial intervertebral disc
JP2007518693A (ja) * 2003-08-18 2007-07-12 ザ バイオ バランス コーポレイション 安定な液体プロバイオティクス組成物、その調製および適用
US7759105B2 (en) 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US7749509B2 (en) 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US20060177424A1 (en) 2003-08-29 2006-08-10 Cobb Mark L Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
US8016816B2 (en) 2003-09-09 2011-09-13 Convatec Technologies Inc. Fecal management appliance and method and apparatus for introducing same
US7541091B2 (en) 2004-05-18 2009-06-02 M & G Usa Corporation Compartmentalized resin pellets for oxygen scavenging
EP1800688A1 (en) 2004-08-05 2007-06-27 Anidral S.R.L. Folic acid producing bifidobacterium bacterial strains, formulations and use thereof
BRPI0418986A (pt) 2004-08-05 2007-12-11 Anidral Srl cepas bacterianas bifidobacterium produtoras de ácido fólico, formulações e seus usos
US20060076536A1 (en) 2004-09-29 2006-04-13 Barshied Scott R Oxygen scavenging pharmaceutical package and methods for making same
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
WO2006127355A2 (en) 2005-05-20 2006-11-30 Dow Global Technologies Inc. Oral drug compliance monitoring using radio frequency identification tags
US20060275223A1 (en) 2005-06-02 2006-12-07 Burr James B Erythritol compositions for teeth and gums
TWI362949B (en) 2005-09-13 2012-05-01 Bion Tech Inc Intestines dissolving nature is able to bear the hydrochloric acid in gastric juice and wrap up the benefit covered and grow the fungus of makes up
CA2635313C (en) 2005-12-29 2013-12-31 Osmotica Corp. Triple combination release multi-layered tablet
JP5006567B2 (ja) 2006-04-14 2012-08-22 花王株式会社 口腔用固形製剤
US7998510B2 (en) 2006-08-17 2011-08-16 C. B. Fleet Company, Inc. Low dose colonic cleansing system
JP2008106066A (ja) 2006-09-25 2008-05-08 Tashiro Yasuaki サポニン及び生菌を含有する組成物
DE102006062250A1 (de) 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
US7645801B2 (en) 2007-01-29 2010-01-12 Alaven Pharmaceutical Llc Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
CA2679480C (en) 2007-03-01 2016-10-18 Probi Ab Use of lactobacillus plantarum for increasing bacterial diversity
AU2008231467A1 (en) 2007-03-28 2008-10-02 Alimentary Health Limited Probiotic Bifidobacterium strains
PL2134833T3 (pl) 2007-03-28 2016-09-30 Probiotyczny szczep Bifidobacterium
CA2687192C (en) 2007-06-04 2015-11-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
CN101707930B (zh) 2007-06-06 2013-10-30 巴斯夫欧洲公司 用于制备快速崩解的片剂的药物配制剂
CN101686931B (zh) 2007-06-06 2013-06-19 巴斯夫欧洲公司 用于制备可咀嚼片剂和锭剂的药物配制剂
EP2264042B1 (en) 2007-07-27 2012-07-18 Cargill, Incorporated Micronization of polyols
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
ATE548423T1 (de) 2007-08-31 2012-03-15 Invista Tech Sarl Sauerstoffabsorbierende kunststoffzusammensetzungen
JP5537943B2 (ja) 2007-09-27 2014-07-02 田辺三菱製薬株式会社 速崩壊性固形製剤
KR101626873B1 (ko) 2007-10-01 2016-06-02 라보라토리오스 레스비, 에스.엘. 구강붕해정제
US20100222311A1 (en) 2007-10-19 2010-09-02 Purdue Research Foundation Solid formulations of crystalline compounds
DK2203551T3 (da) 2007-10-20 2013-10-28 Univ Liege Bifidobakterieart
AU2008317000B2 (en) 2007-10-26 2014-10-23 Brenda E. Moore Probiotic compositions and methods for inducing and supporting weight loss
JP5258268B2 (ja) 2007-11-19 2013-08-07 フロイント産業株式会社 球形粒の製造方法
EP2233129B1 (en) 2007-12-28 2014-05-07 Sawai Pharmaceutical Co., Ltd. Oral cavity disintegrating tablet and method of producing the same
DK3628319T3 (da) 2008-10-02 2024-03-04 Salix Pharmaceuticals Ltd Behandling af hepatisk encefalopati ved anvendelse af rifaximin
US20100178413A1 (en) 2008-12-17 2010-07-15 Mark Gorris Food-based Supplement Delivery System
WO2010103132A1 (es) 2009-03-10 2010-09-16 Hero España, S.A. Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna
US20100255231A1 (en) 2009-04-01 2010-10-07 Multisorb Technologies, Inc. Oxygen scavenging films
EP2424972B1 (en) 2009-04-30 2013-07-24 Actogenix N.V. Cryoprotectants for freeze drying of lactic acid bacteria
US20100285164A1 (en) 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
WO2010138439A1 (en) 2009-05-28 2010-12-02 Aptapharma, Inc. Multiparticulate controlled-release selective serotonin reuptake inhibitor formulations
CN201441672U (zh) 2009-07-14 2010-04-28 赵伟华 一次性灌肠装置
US20110045222A1 (en) 2009-08-19 2011-02-24 Eastman Chemical Company Oxygen-scavenging polymer blends suitable for use in packaging
GB0916335D0 (en) 2009-09-17 2009-10-28 Martin W J Medicaments
US20110081320A1 (en) 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
WO2011046616A2 (en) 2009-10-15 2011-04-21 New York University Methods for modulating bacterial infection
US20110218216A1 (en) 2010-01-29 2011-09-08 Kumaravel Vivek Extended release pharmaceutical composition of donepezil
PL3564357T3 (pl) * 2010-02-01 2022-08-08 Rebiotix, Inc. Bakterioterapia zapalenia jelita grubego z clostridium difficile
US7888062B1 (en) 2010-02-01 2011-02-15 Microbios, Inc. Process and composition for the manufacture of a microbial-based product
US8853269B2 (en) 2010-02-04 2014-10-07 Copperhead Chemical Company Inc. Composition and method for treating infections and promoting intestinal health
BR112012022775A2 (pt) 2010-03-10 2016-07-19 Nogra Pharma Ltd composições para a lavagem, do cólon e métodos para a produção e utilização das mesmas
US9707207B2 (en) 2010-05-26 2017-07-18 The United States Of America As Represented By The Department Of Veterans Affairs Method for diagnosing, preventing, and treating neurological diseases
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
EP2600877A4 (en) 2010-08-04 2014-05-07 Borody Thomas J COMPOSITIONS FOR FLORAL TRANSPLANTATION OF FECAL MATERIALS AND METHODS OF MAKING AND USING SAME, AND DEVICES FOR THEIR ADMINISTRATION
KR20140033309A (ko) 2010-10-04 2014-03-18 브리티쉬 콜롬비아 캔써 에이전시 브랜치 위장 암을 진단하기 위해 위장의 샘플에서의 푸소박테리움의 검출
WO2012048152A2 (en) 2010-10-07 2012-04-12 Mazmanian Sarkis K Probiotic therapies for autism
JP2014507481A (ja) 2011-03-09 2014-03-27 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 結腸微生物相移植のための組成物及び方法
WO2014152484A1 (en) 2013-03-14 2014-09-25 Regents Of The University Of Minnesota Freeze dried fecal microbiota for use in fecal microbial transplantation
US20150374761A1 (en) 2011-03-09 2015-12-31 Regents Of The University Of Minnesota Freeze dried fecal microbiota for use in fecal microbial transplantation
WO2013037068A1 (en) 2011-09-14 2013-03-21 Queen's University At Kingston Method for treatment of disorders of the gastrointestinal system
WO2013053836A1 (en) 2011-10-11 2013-04-18 Quantum Pharmaceuticals Sa Composition comprising anaerobically cultivated human intestinal microbiota
WO2013080561A1 (en) 2011-12-01 2013-06-06 University Of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
WO2013090825A1 (en) 2011-12-15 2013-06-20 Pureflora, Inc. Device for the collection, refinement, and administration of gastrointestinal microflora
CN104662425B (zh) 2012-05-02 2017-10-10 查尔斯河实验室公司 活性染色方法
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
CA2881656C (en) 2012-08-29 2023-07-11 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
BR112015012123A8 (pt) 2012-11-26 2018-01-23 Borody Thomas J composições para a recuperação de uma microbiota fecal e métodos para produzir e usar as mesmas.
EP2951285A4 (en) 2013-02-04 2016-10-26 Seres Therapeutics Inc COMPOSITIONS AND METHODS FOR INHIBITING THE GROWTH OF PATHOGENIC BACTERIA
AU2014239883B2 (en) 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
AU2014262125B2 (en) 2013-04-30 2020-02-13 Thomas Julius Borody Compositions and methods for treating microbiota-related psychotropic conditions and diseases
EP4234011A3 (en) 2013-06-05 2023-09-20 Rebiotix, Inc. Microbiota restoration therapy (mrt), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
EP3019181A4 (en) 2013-07-09 2016-09-21 Puretech Ventures Llc COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MICROFLORE DERIVED MOLECULES FOR THE TREATMENT OF DISEASE
CA2926466C (en) 2013-10-03 2021-11-16 Frederic Bushman Compositions comprising a defined microbiome and methods of use thereof
AU2014352643A1 (en) 2013-11-25 2016-06-30 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
EP3107553B1 (en) 2014-02-18 2021-12-01 Universitätsklinikum Jena Methods and compositions for intestinal microenvironment transfer
SE1550189A1 (en) 2015-02-19 2016-08-20 Achim Biotherapeutics Ab Therapeutic and prophylactic composition produced by microbiota
KR102561989B1 (ko) 2015-05-14 2023-07-31 핀치 테라퓨틱스 홀딩스 엘엘씨 대변 균무리 이식용 조성물, 및 이의 제조 및 사용 방법, 및 이의 전달을 위한 장치
AU2016268158B2 (en) 2015-05-22 2022-03-17 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
CN108472315A (zh) 2015-10-26 2018-08-31 克雷斯顿沃控股公司 用于粪便微生物群相关疗法的组合物及方法
GB2557823A (en) 2016-03-04 2018-06-27 Univ California Microbial consortium and uses thereof

Also Published As

Publication number Publication date
AU2024201513A1 (en) 2024-03-28
ES2636439T3 (es) 2017-10-05
EP3135291A1 (en) 2017-03-01
CA2829385C (en) 2021-07-13
AU2019219826A1 (en) 2019-09-12
CN103561752B (zh) 2016-04-20
AU2021221910A1 (en) 2021-09-23
AU2012225305B2 (en) 2017-06-08
US20170252378A1 (en) 2017-09-07
US10028980B2 (en) 2018-07-24
US11801269B2 (en) 2023-10-31
US20180028574A1 (en) 2018-02-01
US20220110981A1 (en) 2022-04-14
AU2019219826B2 (en) 2021-08-19
US9649343B2 (en) 2017-05-16
EP3610881A1 (en) 2020-02-19
EP4129312A1 (en) 2023-02-08
AU2017203822A1 (en) 2017-06-22
CA3119918A1 (en) 2012-09-13
US20230172993A1 (en) 2023-06-08
MX2013010343A (es) 2014-04-30
US9968638B2 (en) 2018-05-15
US10286011B2 (en) 2019-05-14
US20220339203A1 (en) 2022-10-27
EP2683390B1 (en) 2017-05-03
US20160375063A1 (en) 2016-12-29
BR112013022927A2 (pt) 2016-12-06
US10286012B2 (en) 2019-05-14
US20160279176A1 (en) 2016-09-29
US20140147417A1 (en) 2014-05-29
US20170246214A1 (en) 2017-08-31
WO2012122478A1 (en) 2012-09-13
US20180028573A1 (en) 2018-02-01
CA2829385A1 (en) 2012-09-13
AU2012225305A1 (en) 2013-09-19
PL2683390T3 (pl) 2018-04-30
AU2017203822B2 (en) 2019-09-12
EP2683390A1 (en) 2014-01-15
CN103561752A (zh) 2014-02-05
JP2014507481A (ja) 2014-03-27
AU2021221910B2 (en) 2023-12-07
US20170319627A1 (en) 2017-11-09
SG193348A1 (en) 2013-10-30
US10251914B2 (en) 2019-04-09
US20170326181A1 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
CL2013002573A1 (es) Composición que comprende un extracto o preparación de heces humanas; metodo para reemplazar o complementar o modificar la microbiota de colon de un sujeto; uso de dicha composicion para tratar enfermedad o afección patológica o iatrogénica del colon.
DOP2012000299A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
GT201300243A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
CO6940374A2 (es) Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas
BR112014015851A2 (pt) proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
BRPI1012993A2 (pt) "uso de um anticorpo anti-tau ps422 para o tratamento de doenças do cérebro"
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
BR112015031475A2 (pt) composto, composição farmacêutica, método para tratamento de uma doença ou condição, kit, e, uso de composto.
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015021888A2 (pt) inibidores de dna-ik
BR112013018877A2 (pt) composições farmacêuticas que compreendem anticorpos humanos para pcsk9
BRPI0915112A2 (pt) cateter de entalhe para tratar válvulas cardíacas doentes
BR112016013109A2 (pt) anticorpos de anti-siglec-8 e métodos de seu uso
BR112013001875A2 (pt) cueca masculina com espaço separado para o pênis
BRPI0813456A2 (pt) Composto, uso do mesmo, composição farmacêutica, e, métodos para tratar um mamífero sofrendo de um distúrbio e de uma doença
BR112014016389A8 (pt) composições e uso das mesmas para o tratamento de distúrbios e doenças hepáticas
BR112014008089A2 (pt) método para diagnosticar o mal de alzheimer, uso do método, e, kit para a realização do método
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
BRPI1009781A2 (pt) compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos
ES2627541T8 (es) Métodos para tratar la enfermedad de Parkinson
BR112014009789A2 (pt) cisteamina no tratamento da doença fibrótica